WDR74

Summary

WDR74 (WD repeat domain 74, HGNC:25529) is a protein-coding gene on chromosome 11q12.3, encoding WD repeat-containing protein 74 (Q6RFH5). Regulatory protein of the MTREX-exosome complex involved in the synthesis of the 60S ribosomal subunit. It is a common-essential gene (DepMap: required in 99.8% of cancer cell lines).

Involved in rRNA processing and ribosomal large subunit biogenesis. Located in nuclear exosome (RNase complex); nucleolus; and nucleoplasm.

Source: NCBI Gene 54663 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 39 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 99.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_001369450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25529
Approved symbol	WDR74
Name	WD repeat domain 74
Location	11q12.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10439, Nsa1
Ensembl gene	ENSG00000133316
Ensembl biotype	protein_coding
OMIM	617947
Entrez	54663

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 10 protein_coding, 9 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000278856, ENST00000311713, ENST00000453708, ENST00000525239, ENST00000525752, ENST00000529106, ENST00000536401, ENST00000538098, ENST00000538150, ENST00000538277, ENST00000540620, ENST00000541930, ENST00000542347, ENST00000543688, ENST00000544831, ENST00000544953, ENST00000545112, ENST00000892916, ENST00000934981, ENST00000957922

RefSeq mRNA: 8 — MANE Select: NM_001369450 NM_001307977, NM_001369447, NM_001369448, NM_001369449, NM_001369450, NM_001369451, NM_001369453, NM_018093

CCDS: CCDS44630, CCDS76421

Canonical transcript exons

ENST00000278856 — 11 exons

Exon	Start	End
ENSE00001360892	62839507	62839590
ENSE00002157294	62832911	62833131
ENSE00003480669	62834276	62834331
ENSE00003510848	62835431	62835532
ENSE00003545098	62835695	62835841
ENSE00003551658	62833792	62833937
ENSE00003559893	62834427	62834527
ENSE00003639709	62835961	62836036
ENSE00003670614	62833618	62833674
ENSE00003757010	62839114	62839235
ENSE00003790247	62839322	62839428

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 97.38.

FANTOM5 (CAGE): breadth broad, TPM avg 0.4913 / max 81.2498, expressed in 236 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120245	39.9034	1816
120248	0.4913	236

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.38	gold quality
granulocyte	CL:0000094	94.81	gold quality
body of pancreas	UBERON:0001150	94.51	gold quality
skin of abdomen	UBERON:0001416	94.47	gold quality
right ovary	UBERON:0002118	94.16	gold quality
skin of leg	UBERON:0001511	93.97	gold quality
left uterine tube	UBERON:0001303	93.94	gold quality
gastrocnemius	UBERON:0001388	93.87	gold quality
apex of heart	UBERON:0002098	93.86	gold quality
left ovary	UBERON:0002119	93.77	gold quality
muscle of leg	UBERON:0001383	93.58	gold quality
right uterine tube	UBERON:0001302	93.45	gold quality
lower esophagus mucosa	UBERON:0035834	93.22	gold quality
body of stomach	UBERON:0001161	92.72	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.63	gold quality
right lobe of liver	UBERON:0001114	92.60	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.24	gold quality
cortical plate	UBERON:0005343	92.21	gold quality
tibial nerve	UBERON:0001323	92.17	gold quality
right lobe of thyroid gland	UBERON:0001119	92.16	gold quality
esophagus mucosa	UBERON:0002469	92.13	gold quality
zone of skin	UBERON:0000014	92.10	gold quality
body of uterus	UBERON:0009853	92.03	gold quality
metanephros cortex	UBERON:0010533	91.82	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.82	gold quality
spleen	UBERON:0002106	91.79	gold quality
cerebellar cortex	UBERON:0002129	91.79	gold quality
cerebellar hemisphere	UBERON:0002245	91.76	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.76	gold quality
ovary	UBERON:0000992	91.64	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	3739.92
E-MTAB-7052	yes	2886.50
E-GEOD-76312	yes	1976.07
E-GEOD-70580	yes	1269.33
E-MTAB-6678	yes	767.41
E-CURD-46	yes	15.05
E-ANND-3	yes	9.28
E-GEOD-93593	yes	7.53
E-MTAB-9801	yes	6.11
E-MTAB-7606	no	1038.19
E-ENAD-17	no	368.46
E-CURD-88	no	3.75

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 7)

• results suggest that WDR74 is a novel regulatory protein of the MTR4-exsosome complex whose interaction is regulated by NVL2 and is involved in ribosome biogenesis (PMID:26456651)
• knockdown of WDR74 leads to significant defects in the pre-rRNA cleavage within the internal transcribed spacer 1, occurring in an early stage of the processing pathway. When the dissociation of WDR74 from the MTR4-containing exonuclease complex was impaired upon expression of mutant NVL2, the same processing defect, with partial migration of WDR74 from the nucleolus towards the nucleoplasm, was observed. (PMID:29107693)
• Through direct interactions with Smad proteins, WDR74 enhances TGF-beta-mediated phosphorylation and nuclear accumulation of Smad2 and Smad3. (PMID:30594465)
• WDR74 induces nuclear beta-catenin accumulation and activates Wnt-responsive genes to promote lung cancer growth and metastasis. (PMID:31838084)
• WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway. (PMID:32005977)
• WDR74 rs11231247 contributes to the susceptibility and prognosis of non-small cell lung cancer. (PMID:36701849)
• WDR74 serves as a novel therapeutic target by its oncogenic role in hepatocellular carcinoma. (PMID:37331183)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	wdr74	ENSDARG00000061993
mus_musculus	Wdr74	ENSMUSG00000042729
rattus_norvegicus	Tex54	ENSRNOG00000063481
drosophila_melanogaster	l(2)k09848	FBGN0284246
caenorhabditis_elegans		WBGENE00011538

Protein

Protein identifiers

WD repeat-containing protein 74 — Q6RFH5 (reviewed: Q6RFH5)

Alternative names: NOP seven-associated protein 1

All UniProt accessions (4): E9PS41, Q6RFH5, F5GYL6, H0YFP2

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory protein of the MTREX-exosome complex involved in the synthesis of the 60S ribosomal subunit. Participates in an early cleavage of the pre-rRNA processing pathway in cooperation with NVL. Required for blastocyst formation, is necessary for RNA transcription, processing and/or stability during preimplantation development.

Subunit / interactions. Isoform 1 interacts (through WDR repeats) with NVL; the interaction is independent of RNA or pre-60S ribosome particles. Isoform 2 does not interact with NVL. Interacts with MTREX; the interaction dissociation in a late stage of rRNA synthesis is required for appropriate maturation of pre-60S particles and depends on the ATPase activity of NVL.

Subcellular location. Nucleus. Nucleolus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6RFH5-1	1	yes
Q6RFH5-2	2

RefSeq proteins (8): NP_001294906, NP_001356376, NP_001356377, NP_001356378, NP_001356379, NP_001356380, NP_001356382, NP_060563 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR037379	WDR74/Nsa1	Family

Pfam: PF00400

UniProt features (21 total): repeat 6, modified residue 3, mutagenesis site 3, sequence conflict 3, region of interest 3, chain 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
8FKV	ELECTRON MICROSCOPY	2.47
8FKT	ELECTRON MICROSCOPY	2.81
8FKP	ELECTRON MICROSCOPY	2.85
8FKR	ELECTRON MICROSCOPY	2.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6RFH5-F1	83.28	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 214, 311, 361

Mutagenesis-validated functional residues (3):

Position	Phenotype
171–176	reduces interaction with nvl.
185	reduces interaction with nvl.
191	reduces interaction with nvl.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 189 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, AMIT_SERUM_RESPONSE_20_MCF10A, GOBP_BLASTOCYST_FORMATION, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_BLASTOCYST_DEVELOPMENT, TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA, NRF2_01, GOBP_EMBRYO_DEVELOPMENT, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS, CETS1P54_01, GRADE_COLON_AND_RECTAL_CANCER_UP, GOCC_NUCLEAR_EXOSOME_RNASE_COMPLEX, GOCC_PRERIBOSOME

GO Biological Process (4): blastocyst formation (GO:0001825), rRNA processing (GO:0006364), RNA metabolic process (GO:0016070), ribosomal large subunit biogenesis (GO:0042273)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), preribosome, large subunit precursor (GO:0030687), nuclear exosome (RNase complex) (GO:0000176)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear lumen	3
ribosome biogenesis	2
blastocyst development	1
anatomical structure formation involved in morphogenesis	1
RNA processing	1
rRNA metabolic process	1
nucleic acid metabolic process	1
ribonucleoprotein complex biogenesis	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
intracellular membraneless organelle	1
preribosome	1
exosome (RNase complex)	1
nucleus	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1782 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDR74	EBNA1BP2	Q99848	806
WDR74	WDR12	Q9GZL7	796
WDR74	NSA2	O95478	774
WDR74	NOP2	P46087	768
WDR74	GNL2	Q13823	766
WDR74	NVL	O15381	765
WDR74	MDN1	Q9NU22	763
WDR74	PLEKHS1	Q5SXH7	755
WDR74	RSL24D1	Q9UHA3	744
WDR74	SURF6	O75683	727
WDR74	RPF2	Q9H7B2	716
WDR74	PDCD11	Q14690	708
WDR74	MTREX	P42285	703
WDR74	NMD3	Q96D46	702
WDR74	FTSJ3	Q8IY81	699

IntAct

86 interactions, top by confidence:

A	B	Type	Score
CCT2	TXNDC9	psi-mi:“MI:0914”(association)	0.730
PDCL3	PEX7	psi-mi:“MI:0914”(association)	0.640
CCT3	TXNDC9	psi-mi:“MI:0914”(association)	0.640
CCT5	TXNDC9	psi-mi:“MI:0914”(association)	0.640
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
RCHY1	WDR74	psi-mi:“MI:0915”(physical association)	0.560
WDR74	RCHY1	psi-mi:“MI:0915”(physical association)	0.560
RPL28	MAGEB2	psi-mi:“MI:0914”(association)	0.560
WDR74	RGS2	psi-mi:“MI:0915”(physical association)	0.550
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
CCT7	PEX7	psi-mi:“MI:0914”(association)	0.530
WDR74	DLG4	psi-mi:“MI:0915”(physical association)	0.370
WDR74	NUDT3	psi-mi:“MI:0915”(physical association)	0.370
Brwd3	WDR91	psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350
Gspt1	MRPL27	psi-mi:“MI:0914”(association)	0.350
THOC5	MYO1G	psi-mi:“MI:0914”(association)	0.350
Rrbp1	PIPSL	psi-mi:“MI:0914”(association)	0.350
NOP56	C12orf43	psi-mi:“MI:0914”(association)	0.350
PKN2	TMUB1	psi-mi:“MI:0914”(association)	0.350
NCBP3	ALYREF	psi-mi:“MI:0914”(association)	0.350
IBTK	POP7	psi-mi:“MI:0914”(association)	0.350
Junb	RGPD3	psi-mi:“MI:0914”(association)	0.350
PDGFRA	RNPS1	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (132): WDR74 (Two-hybrid), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), DDX47 (Co-fractionation), DHX37 (Co-fractionation), GNL2 (Co-fractionation), RRS1 (Co-fractionation), WDR74 (Co-fractionation), ZC3H15 (Co-fractionation), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS), WDR74 (Affinity Capture-MS)

ESM2 similar proteins: A1A4I4, A2RRH5, O35465, O35828, O43379, O43818, O60336, P57737, P70268, Q0V8F1, Q12788, Q14318, Q15334, Q16512, Q2KJJ5, Q3B7U9, Q3SZD4, Q3U3T8, Q499N3, Q4VBE8, Q58D06, Q5E9I8, Q5M9G8, Q5R7H5, Q5RF24, Q5U2W5, Q5VW00, Q5ZIW1, Q63433, Q6DKP5, Q6NS57, Q6RFH5, Q8BGW4, Q8BNV1, Q8C4J7, Q8HXL3, Q8IZ69, Q8K4K5, Q8MKF0, Q8TEB1

Diamond homologs: A3LVX0, A5DKC4, A5DX41, A7TJL1, Q58D06, Q5A2T0, Q6BUJ2, Q6CEC9, Q6FU05, Q6RFH5, A6ZU71, O94698, P53136, Q754U4, Q8VCG3, Q54FW9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 114 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	12	21.4×	2e-11
Viral mRNA Translation	12	21.4×	2e-11
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	12	21.2×	2e-11
Association of TriC/CCT with target proteins during biosynthesis	5	20.6×	7e-05
Selenocysteine synthesis	12	20.3×	2e-11
Eukaryotic Translation Termination	12	20.3×	2e-11
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	12	19.9×	2e-11
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	12	19.9×	2e-11

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	12	22.7×	9e-11
translation	13	13.6×	3e-09
regulation of alternative mRNA splicing, via spliceosome	5	12.5×	3e-03
rRNA processing	7	10.1×	5e-04
RNA splicing	9	8.1×	2e-04
mRNA processing	7	5.6×	8e-03
protein stabilization	8	5.5×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	25
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3898494	NR_199791.1(RNU2-2):n.4G>A	Pathogenic

SpliceAI

1381 predictions. Top by Δscore:

Variant	Effect	Δscore
11:62833128:CATC:C	acceptor_gain	1.0000
11:62833787:CTTA:C	donor_loss	1.0000
11:62833788:TTACC:T	donor_loss	1.0000
11:62833789:TA:T	donor_loss	1.0000
11:62833790:A:AT	donor_loss	1.0000
11:62833934:CGCC:C	acceptor_gain	1.0000
11:62833936:CC:C	acceptor_gain	1.0000
11:62833937:CC:C	acceptor_gain	1.0000
11:62833938:C:CC	acceptor_gain	1.0000
11:62834271:CTCA:C	donor_loss	1.0000
11:62834272:TCACC:T	donor_loss	1.0000
11:62834273:CA:C	donor_loss	1.0000
11:62834275:C:CG	donor_loss	1.0000
11:62834327:CTGAG:C	acceptor_gain	1.0000
11:62834328:TGAG:T	acceptor_gain	1.0000
11:62834330:AGC:A	acceptor_loss	1.0000
11:62834332:C:CC	acceptor_gain	1.0000
11:62834345:C:CT	acceptor_gain	1.0000
11:62834346:A:T	acceptor_gain	1.0000
11:62834425:A:AC	donor_gain	1.0000
11:62834426:C:CT	donor_gain	1.0000
11:62834426:CTTG:C	donor_gain	1.0000
11:62835201:T:A	donor_gain	1.0000
11:62835428:TAC:T	donor_loss	1.0000
11:62835429:A:AC	donor_gain	1.0000
11:62835430:C:CC	donor_gain	1.0000
11:62835652:C:CA	donor_gain	1.0000
11:62835693:A:AC	donor_gain	1.0000
11:62835694:C:CC	donor_gain	1.0000
11:62835694:CGTT:C	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000234135 (11:62841665 T>A,C,G), RS1000637928 (11:62837191 T>C), RS1000801544 (11:62838752 T>C), RS1000871249 (11:62833991 C>A,G), RS1001574882 (11:62840112 C>T), RS1001810752 (11:62833317 A>G), RS1002078891 (11:62841691 C>A,G,T), RS1002135294 (11:62843655 G>C), RS1002505091 (11:62836162 A>C), RS1002528384 (11:62841071 C>A), RS1002580903 (11:62841244 G>C,T), RS1002588974 (11:62840572 C>T), RS1003486125 (11:62841850 C>G), RS1003543339 (11:62834886 C>T), RS1003694576 (11:62836397 T>C)

Disease associations

OMIM: gene MIM:617947 | disease phenotypes: MIM:621304

GenCC curated gene-disease

Mondo (2): neurodevelopmental disorder (MONDO:0700092), developmental and epileptic encephalopathy 119 (MONDO:1060177)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST005956_2	Waist-to-hip ratio adjusted for BMI	1.000000e-08
GCST005962_51	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	1.000000e-07
GCST90020025_950	Waist-to-hip ratio adjusted for BMI	4.000000e-08
GCST90020027_1482	Waist-hip index	5.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, affects cotreatment, decreases expression	2
deoxynivalenol	increases expression	2
trichostatin A	decreases expression	2
Acetaminophen	decreases expression	2
Tretinoin	decreases expression	2
Valproic Acid	decreases expression, affects expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
biochanin A	decreases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
sodium arsenite	decreases expression	1
cupric chloride	affects expression	1
nivalenol	increases expression	1
cylindrospermopsin	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Bortezomib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Vehicle Emissions	increases abundance, increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Estradiol	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice